Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
A Phase III trial miss has hollowed out the share price of Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals. 13 January 2023
US a multi-asset longevity biotech Cambrian Biopharma yesterday unveiled its latest pipeline company, as Isterian Biotech. emerged from stealth, headquartered in New York. 13 January 2023
The US Food and Drug Administration’s (FDA) recent approval of TG Therapeutics’ Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a major setback in 2022 when the FDA extended its review of Briumvi by three months. 13 January 2023
Pittsburgh, USA-based clinical-stage biotech Lipella Pharmaceuticals’ shares rose as much as 76% to $5.48, after it announced positive trial results with its bladder disease candidate. 12 January 2023
British biotech Pheno Therapeutics has announced a licensing deal with Belgium’s largest drugmaker UCB, focusing on the science of remyelination. 11 January 2023
Nkarta, a US biopharma developing engineered natural killer (NK) cell therapies to treat cancer, has announced the appointment of a chief medical officer (CMO). 11 January 2023
Privately-held USA-based small-molecule mRNA translation specialist Anima Biotech has entered into other major collaboration, this time with US pharma major AbbVie, which is potentially worth more than $580 million and is aimed at discovering and developing drugs that modulate mRNA biology for three targets in cancer or immune disorders. 11 January 2023
California, USA-based Coherus BioSciences’ shares closed up almost 10% at $9.85 yesterday, when it announced the execution of a binding term sheet with Germany’s Klinge Biopharma for the exclusive US commercialization rights to FYB203, a biosimilar candidate to Eylea (aflibercept). 11 January 2023
Asklepios BioPharmaceutical, the wholly-owned but independently operated subsidiary of Bayer, has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. 10 January 2023
US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany’s Bayer, and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi. 10 January 2023
Massachusetts, USA-based biotech Selecta Biosciences’ shares were up 11% at $1.37, after it announced an exclusive licensing and development agreement with Japan’s Astellas Pharma for IdeXork (Xork). 10 January 2023
Shares of Novavax closed up 11.25% at $12.26 yesterday after it announced a successor for its president and chief executive Stanley Erck, who plans to retire. 10 January 2023
German drugmaker Boehringer Ingelheim and privately-held 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop new cancer therapies. 9 January 2023
Anglo-Irish company Amryt Pharma has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda four years ago. 9 January 2023
Shares of Voyager Therapeutics were up almost 30% at $9.00 pre-market this morning, as it announced a second lucrative strategic collaboration with Neurocrine Biosciences. 9 January 2023
Privately-held Swiss drugmaker Helsinn today announced the appointment of the firm’s current chief operating officer, Dr Melanie Rolli, as group chief executive (CEO) effective from January 1, 2023. 9 January 2023
French pharma firm Ipsen is to acquire the liver disease specialist Albireo, a company focused on the therapeutic potential of bile-acid modulators. 9 January 2023
Boston, USA-based Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, has announced the completion of an $85 million financing. 9 January 2023
After an active M&A year in 2022, UK pharma major AstraZeneca kicked off 2023 with an agreement to acquire USA-based clinical stage biotech CinCor Pharma. 9 January 2023